A Multiplex Protein Microarray Platform for Preclinical Tissue Binding and Cross-Reactivity of Therapeutic Antibodies
- 1JeiserBio inc.
Abstract
The NexAb multiplex protein microarray platform, comprising a 7,015-spot tissue lysate array and antigen-oriented protein arrays, was developed for preclinical tissue-binding and cross-reactivity assessment of therapeutic antibodies. Four anti-HER2 antibodies, trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), were profiled with integrated ERBB2 mRNA data. On antigen-oriented arrays, cell-synthesized HER2 bound trastuzumab and pertuzumab strongly and epitope-dependently, whereas wheat-germ HER2 showed no binding. On the tissue lysate array, trastuzumab and T-DM1 bound HER2-positive cancer cell lines and tumor tissues with nearly identical profiles (correlation coefficient r = 0.991), and T-DXd bound ERBB2-low cancer spots and 38.8% of normal human tissue spots, a profile not conserved in cynomolgus monkeys. Trastuzumab, T-DM1, and pertuzumab showed no cross-reactivity with cynomolgus monkey tissues, whereas T-DXd bound 3.1% of monkey tissue spots. NexAb enables quantitative cross-reactivity profiling relevant to preclinical safety evaluation.
Related
- Monoclonal antibodies raised against the Junín virus glycoprotein show broad reactivity and provide protection in vivo
- Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers
- CD47–SIRPα as a Therapeutic Target in Sarcoma: A Systematic Review of Expression, Preclinical, and Clinical Evidence
- ANTIBODIES AND PLASMA COMPONENTS CONTRIBUTE DIFFERENTLY TO PLATELET REACTIVITY IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
- Multiproperty optimization of therapeutic antibodies through sequence editing via large language model and reinforcement learning
BibTeX
@misc{matsukura2026multiplex,
title = {{A Multiplex Protein Microarray Platform for Preclinical Tissue Binding and Cross-Reactivity of Therapeutic Antibodies}},
author = {S. Matsukura and N. Sawada and M. Watanabe and I. Yabuta and G. Morisawa and Y. Kawamura and H. Nanamiya and J.-i. Imai and M. Takagi},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.11.757820},
url = {https://www.biorxiv.org/content/10.64898/2026.10.11.757820v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - A Multiplex Protein Microarray Platform for Preclinical Tissue Binding and Cross-Reactivity of Therapeutic Antibodies
AU - S. Matsukura
AU - N. Sawada
AU - M. Watanabe
AU - I. Yabuta
AU - G. Morisawa
AU - Y. Kawamura
AU - H. Nanamiya
AU - J.-i. Imai
AU - M. Takagi
PY - 2026
DA - 2026/10/11
PB - bioRxiv
DO - 10.64898/2026.10.11.757820
UR - https://www.biorxiv.org/content/10.64898/2026.10.11.757820v1
AB - The NexAb multiplex protein microarray platform, comprising a 7,015-spot tissue lysate array and antigen-oriented protein arrays, was developed for preclinical tissue-binding and cross-reactivity assessment of therapeutic antibodies. Four anti-HER2 antibodies, trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), were profiled with integrated ERBB2 mRNA data. On antigen-oriented arrays, cell-synthesized HER2 bound trastuzumab and pertuzumab strongly and epitope-dependently, whereas wheat-germ HER2 showed no binding. On the tissue lysate array, trastuzumab and T-DM1 bound HER2-positive cancer cell lines and tumor tissues with nearly identical profiles (correlation coefficient r = 0.991), and T-DXd bound ERBB2-low cancer spots and 38.8% of normal human tissue spots, a profile not conserved in cynomolgus monkeys. Trastuzumab, T-DM1, and pertuzumab showed no cross-reactivity with cynomolgus monkey tissues, whereas T-DXd bound 3.1% of monkey tissue spots. NexAb enables quantitative cross-reactivity profiling relevant to preclinical safety evaluation.
ER -